7 cough syrups have been singled out by the World Health Organization in its investigation into the distribution of tainted cough syrups throughout the globe, according to the NDTV channel.
Twenty hazardous drugs were identified by the WHO investigation, and their use is blamed for more than 300 deaths globally. According to WHO officials speaking to NDTV, the remaining pharmaceutical goods on the list are from Indonesia.
The primary manufacturers of these dangerous 7 cough syrups are Maiden Pharmaceuticals, Marion Biotech, and QP Pharma Chem, all situated in Haryana. Notably, WHO has previously issued a warning about tainted medications produced in India, but this time the list was released following the conclusion of a thorough study.
In its investigation, the WHO discovered significant levels of diethylene and ethylene glycol in cough syrups, which contributed to several fatalities all around the world. After several deaths linked to cough syrup usage were recorded in African nations, India’s supply of subpar medications came to light. More than 60 youngsters in the Gambia and over 20 in Uzbekistan passed away due to medications produced in India last year.
Ethylene glycol and diethylene glycol, two hazardous substances, were discovered in the syrup prescriptions.
An earlier investigation by the US Centers for Disease Control and Prevention (CDC) and the Gambian health authorities revealed a clear correlation between the use of cough syrups produced in India and the deaths of numerous children in the Gambia.
An additional 12 deaths in Africa’s Cameroon have been connected to cough syrups produced in India.
In a recent event, the Central African nation of Cameroon stated that tainted cough syrups were to blame for twelve child deaths. The authorities anticipate that using drugs produced in India will cause youngsters to die.
According to Bloomberg, which had access to the photo given by Cameroonian health officials, the tainted medications were produced by Riemann Labs Pvt. Ltd., which has its headquarters in Indore, Madhya Pradesh.
The medications in the image “look like ours,” Riemann director Navin Bhatia told Bloomberg in a phone interview. Reimann adheres to tight quality standards; therefore, there is no chance that it produced contaminated medicine or even hinted at counterfeiting, he added.
